The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
Hansjochen Wilke
Honoraria - Lilly
Eric Van Cutsem
Research Funding - Lilly
Sang Cheul Oh
No relevant relationships to disclose
Gyorgy Bodoky
No relevant relationships to disclose
Yasuhiro Shimada
Honoraria - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
Shuichi Hironaka
No relevant relationships to disclose
Naotoshi Sugimoto
Honoraria - Osaka GI Cancer Meeting
Research Funding - Meeting of HER-2 Positive Cancer
Oleg N. Lipatov
No relevant relationships to disclose
Tae-You Kim
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Atsushi Ohtsu
No relevant relationships to disclose
Philippe Rougier
Disclosure not yet available
Michael Emig
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Roberto Carlesi
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Kumari Chandrawansa
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Kei Muro
No relevant relationships to disclose